This article reviews the pathology and management of peripheral nerve tumours, including a framework for investigation and decision-making. Most tumours are benign, including schwannomas and neurofibromas, but malignant peripheral nerve sheath tumours can occur. The risk of malignant change is remote for schwannomas but higher for neurofibromas, particularly in neurofibromatosis type 1. Magnetic resonance imaging is useful for defining the relationship of a swelling with adjacent nerves but is not definitive for tissue diagnosis. Increasing size, pain and neurological deficit suggest malignant change and TruCut needle biopsy is indicated, although there is a risk of sampling error. Excision biopsy preserving nerve function may be carried out for benign tumours to relieve symptoms. Malignant tumours require a multidisciplinary approach. Complete surgical excision with clear margins is the only curative treatment and may be supplemented with radiotherapy and chemotherapy. However, prognosis remains poor, particularly for patients with neurofibromatosis.
AlfonsoDTSotrelAGrossmanJAI.Carpal tunnel syndrome due to an intraneural perineurioma in a 2-year-old child. J Hand Surg Br. 2001,
26: 168–70.
2.
AmirianESGoodmanJCNewPScheurerME.Pediatric and adult malignant peripheral nerve sheath tumors: an analysis of data from the surveillance, epidemiology, and end results program. J Neurooncol. 2014,
116: 609–16.
3.
AntonescuCScheithauerBWWoodruffJM.Tumors of the peripheral nervous system: AFIP atlas of tumor pathology, 4th Series.
Silver Spring,
ARP Press, 2013.
CarrioMGelBTerribasE, et al.
Analysis of intratumor heterogeneity in neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: correlating histological and genomic findings. Hum Mutat. 2018,
39: 1112–25.
6.
DicksonMAMahoneyMRTapWD, et al.
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. Ann Oncol. 2016,
27: 1855–60.
7.
DunnGPSpiliopoulosKPlotkinSR, et al.
Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. J Neurosurg. 2013,
118: 142–8.
8.
FernerREGoldingJFSmithM, et al.
[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008,
19: 390–4.
9.
FernerREGutmannDH.International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002,
62: 1573–7.
10.
FerrariAMiceliRReyA, et al.
Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J Cancer. 2011,
47: 724–31.
11.
GeitenbeekRTJMartinEGravenLH, et al.
Diagnostic value of 18F‑FDG PET‑CT in detecting malignant peripheral nerve sheath tumours among adult and paediatric neurofibromatosis type 1 patients. J Neurooncol. 2022,
156: 559–67.
12.
GrossAWoltersPBaldwinA, et al.
NFM-07. Sprint: phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN). Neuro Oncol. 2018,
20 (Suppl 2): i143–44.
13.
GruenJPMitchellWKlineDG.Resection and graft repair for localized hypertrophic neuropathy. Neurosurgery. 1998,
43: 78–83.
14.
GürkanVSeverGKaracaGOrhunHBilgiçB.Re: Intraneural perineurioma of the median nerve. A rare cause of carpal tunnel syndrome. J Hand Surg Eur. 2008,
33: 88–9.
15.
HagenmaierHSFvan BeeckAGKHaasRL, et al.
The influence of Personalised Sarcoma Care (PERSARC) prediction modelling on clinical decision making in a multidisciplinary setting. Sarcoma. 2021,
2021: 8851354.
HemsTEJBurgePDWilsonDJ.The role of magnetic resonance imaging in the management of peripheral nerve tumours. J Hand Surg Br. 1997,
22: 57–60.
18.
HighamCSSteinbergSMDombiE, et al.
SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy-naive malignant peripheral nerve sheath tumors. Sarcoma. 2017,
2017: e8685638.
19.
HornickJLFletcherCD.Soft tissue perineurioma: clinicopathologic analysis of 81 cases including those with atypical histologic features. Am J Surg Pathol. 2005,
29: 845–58.
20.
IsaacSAthanasouNAPikeMBurgePD.Radial nerve palsy owing to localized hypertrophic neuropathy (intraneural perineurioma) in early childhood. J Child Neurol. 2004,
19: 71–5.
21.
JessenKRMirskyR.The origin and development of glial cells in peripheral nerves. Nat Rev Neurosci. 2005,
6: 671–82.
22.
KahnJGillespieATsokosM, et al.
Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol. 2014,
4: 324.
23.
KainhoferVSmolleMASzkanderaJ, et al.
The width of resection margins influences local recurrence in soft tissue sarcoma patients. Eur J Surg Oncol. 2016,
42: 899–906.
24.
KangYPekmezciMFolpeALErsenAHorvaiAE.Diagnostic utility of SOX10 to distinguish malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial sarcoma. Mod Pathol. 2014,
27: 55–61.
25.
KaramchandaniJRNielsenTOvan de RijnMWestRB.Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohistochem Mol Morphol. 2012,
20: 445–50.
26.
Kehrer-SawatzkiHFarschtschiSMautnerVFCooperDN.The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. Hum Genet. 2017,
136: 129–48.
27.
KnightDMBirchRPringleJ.Benign solitary schwannomas: a review of 234 cases. J Bone Joint Surg Br. 2007,
89: 382–7.
28.
KnightSWEKnightTESantiagoTMurphyAJAbdelhafeezAH.Malignant peripheral nerve sheath tumors-a comprehensive review of pathophysiology, diagnosis, and multidisciplinary management. Children (Basel). 2022,
9: 38.
29.
LassalettaLTorres-MartinMPena-GraneroC, et al.
NF2 genetic alterations in sporadic vestibular schwannomas: clinical implications. Otol Neurotol. 2013,
34: 1355–61.
30.
MartinECoertJHFluckeUE, et al.
Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: a nationwide cohort study. Pediatr Blood Cancer. 2020a,
67: e28138.
31.
MartinECoertJHFluckeUE, et al.
A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer. 2020b,
124: 77–87.
32.
MartinEFluckeUECoertJHvan NoeselMM.Treatment of malignant peripheral nerve sheath tumors in pediatric NF1 disease. Childs Nerv Syst. 2020c,
36: 2453–62.
33.
MartinEGeitenbeekRTJCoertJH, et al.
A Bayesian approach for diagnostic accuracy of malignant peripheral nerve sheath tumors: a systematic review and meta-analysis. Neuro Oncol. 2021,
23: 557–71.
34.
MartinEPendletonCVerhoefCSpinnerRJCoertJH; MONACO collaborators.
Morbidity and function loss after resection of malignant peripheral nerve sheath tumors. Neurosurgery. 2022,
90: 354–64.
35.
MauermannMLAmramiKKKuntzNL, et al.
Longitudinal study of intraneural perineurioma–a benign, focal hypertrophic neuropathy of youth. Brain. 2009,
132: 2265–76.
36.
McMenaminMEFletcherCD.Expanding the spectrum of malignant change in schwannomas: epithelioid malignant change, epithelioid malignant peripheral nerve sheath tumor, and epithelioid angiosarcoma: a study of 17 cases. Am J Surg Pathol. 2001,
25: 13–25.
37.
MiaoRWangHJacobsonA, et al.
Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiother Oncol. 2019,
137: 61–70.
38.
MitsumotoHWilbournAJGorenH.Perineurioma as the cause of localized hypertrophic neuropathy. Muscle Nerve. 1980,
3: 403–12.
39.
OhJEOhtaTSatomiK, et al.
Alterations in the NF2/LATS1/LATS2/YAP pathway in Schwannomas. J Neuropathol Exp Neurol. 2015,
74: 952–9.
40.
OrtonneNWolkensteinPBlakeleyJO, et al.
Cutaneous neurofibromas: current clinical and pathologic issues. Neurology. 2018,
91 (2 Suppl 1): S5–S13.
41.
OtsukaHKohashiKYoshimotoM, et al.
Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors. Pathol Res Pract. 2018,
214: 417–25.
42.
PanwarJSJakkaniRKThomasBP.MR imaging of nontraumatic intrinsic brachial plexus neuropathy: spectrum of findings. J Nucl Med Radiat Ther. 2015,
5: 246.
43.
PanwarJMathewAThomasBP.Cystic lesions of peripheral nerves: are we missing a diagnosis of intraneural ganglion cysts. World J Radiol. 2017,
9: 230–44.
44.
PapaliaHAudicFRivièreGRVerschuurAAndréN.Quick and sustained clinical response to MEK inhibitor I in a NF1 patient with neurofibromas. Ecancermedicalscience. 2018,
12: 862.
45.
ParkMJSeoKNKangHJ.Neurological deficit after surgical enucleation of schwannomas of the upper limb. J Bone Joint Surg Br. 2009,
91: 1482–6.
46.
PekmezciMCuevas-OcampoAKPerryAHorvaiAE.Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. Mod Pathol. 2017,
30: 1710–9.
47.
PemovAHansenNFSindiriS, et al.
Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define pre-malignant neurofibromatosis type 1-associated atypical neurofibromas. Neuro Oncol. 2019,
21: 981–92.
48.
PemovALiHPatidarRHansenNF, et al.
The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas. Oncogene. 2017,
36: 3168–77.
49.
Prieto-GranadaCNWiesnerTMessinaJLJungbluthAAChiPAntonescuCR.Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am J Surg Pathol. 2016,
40: 479–89.
50.
PrudnerBCBallTRathoreRHirbeAC.Diagnosis and management of malignant peripheral nerve sheath tumors: current practice and future perspectives. Neurooncol Adv. 2020,
2 (Suppl 1): i40–9.
51.
ReillyKMKimABlakelyJ, et al.
Neurofibromatosis type 1-associated MPNST state of the science: outlining a research agenda for the future. J Natl Cancer Inst. 2017,
109: djx124.
52.
RibeiroSNapoliIWhiteIJ, et al.
Injury signals cooperate with NF1 loss to relieve the tumor-suppressive environment of adult peripheral nerve. Cell Rep. 2013,
5: 126–36.
53.
RohrichMKoelscheCSchrimpfD, et al.
Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol. 2016,
131: 877–87.
54.
SambriACaldariEFioreM, et al.
Margin assessment in soft tissue sarcomas: review of the literature. Cancers (Basel). 2021,
13: 1687.
55.
SawadaTSanoMOgiharaHOmuraTMiuraKNaganoA.The relationship between pre-operative symptoms, operative findings and postoperative complications in schwannomas. J Hand Surg Br. 2006,
31: 629–34.
56.
SchaeferIMFletcherCD.
Malignant peripheral nerve sheath tumor (MPNST) arising in diffuse-type neurofibroma: Clinicopathologic characterization in a series of 9 cases. Am J Surg Pathol. 2015,
39: 1234–41.
57.
SharifSFernerRBirchJM, et al.
Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol. 2006,
24: 2570–5.
58.
StuckyCCHJohnsonKNGrayRJ, et al.
Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012,
19: 878–85.
59.
ThomasPBertholdCOchoaJ.Microscopic anatomy of the peripheral nervous system. In: DyckPThomasP (Eds.) Peripheral neuropathy, 3rd Edn.
Philadelphia,
WB Saunders, 1993: 28–91.
60.
TovmassianDAbdul RazakMLondonK.The role of [18F]FDG-PET/CT in predicting malignant transformation of plexiform neurofibromas in neurofibromatosis-1. Int J Surg Oncol. 2016,
2016: 6162182.
61.
UusitaloERantanenMKallionpääRA, et al.
Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016,
34: 1978–86.
62.
ValentinTLe CesneARay-CoquardI, et al.
Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016,
56: 77–84.
63.
World Health Organization. Soft tissue and bone tumours. In: WHO Classification Tumours Editorial Board (Eds.) WHO classification of tumours, 5th Edn.
Geneva,
WHO, 2020, Vol.
3, 226–60.
64.
WoodruffJMSeligAMCrowleyKAllenPW.Schwannoma (neurilemoma) with malignant transformation: a rare distinctive peripheral nerve tumour. Am J Surg Pathol1994,
18: 882–95.
65.
YangJCChangAEBakerAR, et al.
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998,
16: 197–203.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
